Equities Analysts Set Expectations for Elevance Health, Inc.'s Q4 2024 Earnings (NYSE:ELV)

Elevance Health, Inc. (NYSE:ELV - Free Report) - Investment analysts at Wolfe Research raised their Q4 2024 earnings estimates for shares of Elevance Health in a research report issued on Monday, September 23rd. Wolfe Research analyst J. Lake now anticipates that the company will post earnings per share of $6.79 for the quarter, up from their previous estimate of $6.76. The consensus estimate for Elevance Health's current full-year earnings is $37.25 per share. Wolfe Research also issued estimates for Elevance Health's Q2 2025 earnings at $11.43 EPS, Q4 2025 earnings at $7.83 EPS, FY2025 earnings at $41.69 EPS and FY2028 earnings at $57.82 EPS.

A number of other research analysts have also recently issued reports on ELV. Robert W. Baird initiated coverage on shares of Elevance Health in a research note on Thursday, May 30th. They issued an "outperform" rating and a $649.00 price objective on the stock. Stephens reissued an "overweight" rating and issued a $615.00 price objective on shares of Elevance Health in a research note on Thursday, September 5th. Baird R W raised shares of Elevance Health to a "strong-buy" rating in a research note on Thursday, May 30th. Royal Bank of Canada lifted their price objective on shares of Elevance Health from $575.00 to $585.00 and gave the company an "outperform" rating in a research note on Thursday, July 18th. Finally, Wells Fargo & Company decreased their price objective on shares of Elevance Health from $600.00 to $593.00 and set an "overweight" rating on the stock in a research note on Monday, July 22nd. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of "Buy" and an average price target of $604.29.

Elevance Health Price Performance

Shares of NYSE ELV traded down $0.21 during midday trading on Thursday, reaching $520.28. The company's stock had a trading volume of 724,027 shares, compared to its average volume of 1,007,815. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.49 and a current ratio of 1.49. Elevance Health has a fifty-two week low of $431.38 and a fifty-two week high of $567.26. The business's 50 day moving average price is $535.75 and its two-hundred day moving average price is $529.81. The company has a market cap of $120.92 billion, a P/E ratio of 19.66, a P/E/G ratio of 1.17 and a beta of 0.82.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Wednesday, July 17th. The company reported $10.12 earnings per share for the quarter, beating analysts' consensus estimates of $9.99 by $0.13. Elevance Health had a net margin of 3.89% and a return on equity of 20.64%. The company had revenue of $43.22 billion during the quarter, compared to the consensus estimate of $42.99 billion. During the same period in the previous year, the business earned $9.04 earnings per share. The firm's quarterly revenue was down .4% on a year-over-year basis.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th were issued a $1.63 dividend. The ex-dividend date was Tuesday, September 10th. This represents a $6.52 annualized dividend and a yield of 1.25%. Elevance Health's payout ratio is 24.64%.

Insider Activity at Elevance Health

In other news, Director Ramiro G. Peru sold 753 shares of the company's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the transaction, the director now owns 8,744 shares in the company, valued at $4,647,610.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Ramiro G. Peru sold 753 shares of the business's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the sale, the director now directly owns 8,744 shares of the company's stock, valued at $4,647,610.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert L. Dixon, Jr. sold 305 shares of the business's stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $506.76, for a total transaction of $154,561.80. Following the sale, the director now directly owns 9,721 shares of the company's stock, valued at $4,926,213.96. The disclosure for this sale can be found here. Insiders have sold a total of 35,058 shares of company stock worth $17,588,116 over the last quarter. Company insiders own 0.35% of the company's stock.

Institutional Investors Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently made changes to their positions in ELV. Bank & Trust Co bought a new stake in Elevance Health in the 2nd quarter worth about $27,000. Pin Oak Investment Advisors Inc. bought a new stake in Elevance Health in the 4th quarter worth about $28,000. Palisade Asset Management LLC bought a new stake in Elevance Health in the 1st quarter worth about $28,000. Opal Wealth Advisors LLC bought a new stake in Elevance Health in the 2nd quarter worth about $28,000. Finally, Strategic Financial Concepts LLC bought a new position in shares of Elevance Health during the 2nd quarter valued at approximately $30,000. 89.24% of the stock is owned by institutional investors.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.